Introduction
Prognosis of intrahepatic cholangiocarcinoma (iCCA) remains dismal. Since this results in part from delayed diagnosis, there is a need to understand the mechanisms that drive development of precancerous lesions and their progression towards malignant tumor. 1 A range of perturbed signaling pathways and genomic alterations was found to be associated with late-stage cholangiocarcinoma, but there is still limited knowledge about how such pathways and mutations evolve throughout tumorigenesis. [2] [3] [4] [5] [6] [7] [8] Moreover, our understanding of this process is further complicated by the observation that iCCA can arise from several cell types, namely cholangiocytes, hepatocytes, progenitor cells and peribiliary glands. [9] [10] [11] [12] [13] [14] [15] [16] Histopathological studies identified two subtypes of iCCA in humans. Small duct subtype is typically located at the periphery of the liver and presents as tubular-type adenocarcinoma with cuboidal cells and ductular component without mucin production.
The large duct subtype is predominantly found near the hilum and exhibits a tubular pattern with mucin-producing columnar cells. 17 Histopathological studies classified biliary intraepithelial neoplasia (BilIN), intraductal tubulopapillary neoplasms and intraductal papillary neoplasms of bile ducts (IPNB) as non-invasive precursor lesions. [18] [19] [20] Whereas BilINs develop in large bile ducts and present as flat or micropapillary dysplasia of the bile duct epithelium, IPNBs are macroscopic lesions of the large ducts characterized by exophytic papillary structures with fibrovascular core and prominent intraductal growth. 21, 22 Biliary micro-hamartomas, also called von Meyenburg complexes, are irregular ductal structures surrounded by dense stroma.
These complexes are considered benign, but were reported to evolve towards iCCA in rare instances and potentially qualify as iCCA precursor lesion. 23 Gain-of-function mutations of the small GTPase v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) are detected in iCCA at a frequency of 15-25%, and are associated with a significant decrease of survival. [24] [25] [26] [27] [28] Importantly, KRAS mutations were detected in BilINs and IPNBs in 25-50% of cases, strongly suggesting that such mutations contribute to initiate tumorigenesis. [29] [30] [31] Chronic inflammation is a well known risk factor of iCCA. Patients with primary sclerosing cholangitis are at high risk for iCCA -5 - and molecular classification of late-stage cholangiocarcinomas underscored the importance of inflammatory gene expression in iCCA pathogeny. [32] [33] [34] Animal models are invaluable for investigating intra-and extrahepatic CCA development, and several models were designed based on induction of cholestasis, administration of tumor-promoting agents, injection of tumor cells, and generation of genomic alterations. [35] [36] [37] However, limited attention was paid to tumor initiation and progression, and in several instances genetic alterations were induced at the prenatal stage or simultaneously in hepatocytes and cholangiocytes, unlike in humans. Here, we generated an original mouse model of iCCA tumorigenesis in which expression of the oncogenic mutant Kras G12D is specifically induced in cholangiocytes and is combined with diet-induced inflammation that mimics chronic cholangitis. The mice developed IPNB similar to those in humans, and our data support that those lesions evolve toward malignant iCCA. We also identified a gene regulatory pathway that is activated during tumorigenesis and which promotes cell proliferation and migration.
Material and Methods

Animals
Osteopontin-iCreERT 2 (Opn-Cre ER ), loxP-stop-loxP-Kras G12D/+ (LSL-Kras G12D/+ ) and Rosa26R eYFP mice were described [38] [39] [40] and bred in a CD1-enriched background. For Cre-LoxP recombination, 6 week-old mice were injected intraperitoneally three times at one day interval with tamoxifen (T5648; Sigma-Aldrich, Bornem, Belgium) dissolved in corn oil at a concentration of 30 mg/mL and at a dose of 150 mg/kg of body weight.
Mice were fed a standard diet or a diet containing 3,5-diethoxycarbonyl-1,4 dihydrocollidine 0.1% (DDC; 137030 Sigma-Aldrich) and monitored for signs of illness as described in the Results section and in Supplementary Figure 1 
Plasmids, sub-cloning and mutagenesis
Kras G12D , Sox17, and Tns4 cDNAs were polymerase chain reaction (PCR)-amplified using the primers listed in Supplementary Table 1 For transient transfections, cells were grown in 60 mm dishes and transfected with 3 µg plasmid, using jetPRIME® (Polyplus-Transfection, Illkirch-Graffenstaden, France) for 24 h, in at least three independent experiments. DNA was transfected 24 h after plating the cells on 60 mm dishes, and the medium was changed every day. For stable transfections, NMC or EGI-1 cells were grown in 35 mm dishes. Cells in each well were transfected with 1.9 µg plasmid (pSBtet-GN, pSBtet-GN-SOX17 or pSBtet-GN-TNS4) and 100 ng of pCMV(CAT)T7-SB100 vector, using jetPRIME® (Polyplus-Transfection, Illkirch-Graffenstaden, France). Twenty-four hours after transfection, cells were subjected to 1 mg/mL G418 for 7 days. GFP-positive cells were sorted using FACSAria III (BD, Franklin Lakes, USA) and distributed one cell per well for clonal selection. After growth for 5 days in DMEM, 10% FBS, 2 mM L-Glutamine, Penicillin-Streptomycin (50 -7 -U/mL and 50 µg/mL), 2.5 µg/mL Amphotericin B and 10% NEAA, each clone was treated with 1 mg/mL G418 for 2 weeks and the stability of the transfected vectors was monitored by detecting GFP fluorescence. Cells were treated with 0.5 µg/mL doxycycline for 5 days to induce SOX17 and TNS4.
Laser capture microdissection (LCM), RNA extraction and sequencing
The livers were collected, embedded in OCT, frozen in liquid nitrogen and stored at −80 °C until processing. Microscope support glass, membrane slides and all tools were pre-treated to remove RNAse (RNaseZAP, Sigma-Aldrich). Ten µm sections were cut using Cryostar NX70 (Thermo Fisher Scientific) at -25°C for knife/blade temperature and -13°C for specimen temperature. Liver sections were deposited on slides adapted for LCM (SuperFrost Plus (25x75x1mm); VWR, Leuven, Belgium) and stored at -80°C inside plastic containers with silica granules to prevent tissue hydration. Within 12h, the liver sections were microdissected using Leica LMD7000 microscope (GIGA, Liège, Belgium) and RNA was directly extracted with RNAqueous®-Micro total RNA isolation AM1931 Kit (Thermo Fisher Scientific). RNA was stored at -80°C. 
Bioinformatics analysis workflow
Read quality control was performed using FastQC software v0.11.7 (Babraham Institute, Cambridge, UK). Low quality reads were trimmed and adapters were removed using Trimmomatic software v0.35 (RWTH Aachen University, Germany).
Reads were aligned using HISAT2 software v2.1.0 (Johns Hopkins University School -8 -of Medicine, Center for Computational Biology, Baltimore, MD, USA) on GRCm38 mouse genome. Gene counts were generated using HTSeq-count (v0.5.4p3) software 44, 45 and gencode.vM15.annotation.gtf annotation file. Differential expression analysis were done using DESeq2 v1.22.2, 46 on R version 3.5.1. Differential expression analyses were performed using adjusted p-value <0.05 and log foldchange <0.01. All differential expression data are relative data from normalized transcript per million (TPM). Pearson correlation analyses were performed using 'rcorr' function from the Hmisc package (RStudio). 
Cell proliferation assays
Cell migration assay
7x10 3 EGI-1 or 1.5x10 4 NMC cells, wild-type or overexpressing doxycycline-induced TNS4, were plated at day 1 in culture-insert 2 wells installed in µ-Dish 35mm,high (#81176, Ibidi Gmgh, Gräfelfing, Gemany) and grown for 48 h. Then, the culture-inserts 2 wells were removed leaving a wound of about 200 μm between the two wells. Six adjacent pictures covering the entire wound were taken at 0h, 1h, 3h, 6h and 8h of culture.
Three wound distances were measured on each picture with 50 µm interval between each measurement (ZEN Blue v2.5 software, Carl Zeiss Vision, Oberkochen,
Germany). -9 - Single comparisons between two experimental groups were done using a paired Student's t test. To identify significant differences between multiple groups, statistical analyses were performed using a one-way ANOVA followed by Newman-Keuls test.
Statistical analyses
For adjusted p-value, a Benjamini-Hochberg correction was applied. For all analyses, p-value<0.05 was considered significant. All statistical analyses were done using the Prism software (GraphPad softwares).
Animal housing and numbers, Western blotting, Reverse Transcriptionquantitative PCR, cholangiocyte purification, tissue staining procedures
See supplementary information
Results
Cholangiocyte-specific expression of Kras G12D combined with DDC-induced cholangitis causes stepwise development of IPNB and iCCA.
To recapitulate the tumorigenic process of human iCCA, we generated a mouse model which combines cholangiocyte-specific Kras G12D expression with chronic cholangitis.
Opn-Cre ER mice, which express tamoxifen-inducible Cre ER recombinase specifically in cholangiocytes, were mated with LSL-Kras G12D/+ mice, which contain a mutated Kras allele coding for KRAS G12D when a loxP-flanked cassette has been removed by CreERmediated recombination. [38] [39] [40] The mice also contained a tamoxifen-inducible Rosa26R eYFP allele. Kras G12D expression was induced by administration of tamoxifen to 6 week-old mice. Mice were then fed a normal diet for 4 weeks to enable wash out of tamoxifen. Thereafter, chronic cholangitis was induced by feeding the mice a 3,5diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet, as described by Fickert and coworkers. 47 To this end, the mice received a DDC diet which was interrupted after 2 weeks because of weight loss. Following 1 week of weight recovery under normal diet, DDC diet was resumed, and livers were collected after 8 and 18 weeks of cholangitis, and at several time points between 21 and 31 weeks of cholangitis ( Figure 1A ). During this period the mice accepted the DDC diet; the experiments were interrupted when animals showed signs of severe illness and had reached humane endpoints (Supplementary Figure 1A-B ). Importantly, starting at 21 weeks of DDC diet, iCCAs were observed, but only in mice combining DDC-induced cholangitis and cholangiocyte-specific Kras G12D expression ( Figure 1C ). iCCAs developed in one third of cases (12/36 males; 9/24 females). iCCA histology showed tubular structures with desmoplastic changes typical of human cholangiocarcinoma ( Figure 1C ). iCCAs were highly proliferative as illustrated by Ki67 staining, and expressed cytokeratin 19 (CK19) and epithelial cell adhesion molecule (EpCAM); they also expressed eYFP, supporting their biliary origin ( Figure 2A ). The epithelium was columnar to cuboidal, and was mucin-positive as shown by alcian blue staining ( Figure 2B ). This phenotype is similar to the human mucin-producing large duct type iCCA. Some tumors appeared less desmoplastic ( Figure 2B ). Interestingly, adjacent to large ducts, we often found areas of glandular proliferation with expansive growth pattern and cytonuclear atypia, which we qualified as early stage of invasive cancer ( Figure 2C ). Importantly, focal transitions between IPNB and early invasive cancer were detected, suggesting that IPNB evolved to iCCA (arrows in Figure 2C ).
We concluded that the mouse model develops IPNB and iCCA which faithfully recapitulate the histology of their human counterparts. - 
-
Signaling pathways known to drive iCCA development in humans are activated in the mouse model.
To investigate the status of signaling pathways often perturbed in human iCCA, we first evaluated mitogen activated protein kinase (MAPK) activity and looked at phosphorylated extracellular-regulated kinase (p-ERK). 48 p-ERK was detected in cholangiocytes following Kras G12D induction or DDC treatment, and in iCCA, but not in untreated normal cholangiocytes ( Figure 3A) . Second, phosphoinositide-3-kinase (PI3K) 48 was found to be activated in IPNB cells of DDC-treated mice expressing wildtype Kras, and in iCCA of DDC-treated mice expressing mutant Kras G12D , as evidenced by staining with anti-phosphorylated AKT serine/threonine kinase (p-AKT) ( Figure 3A) .
Third, we also detected accumulation of hairy and enhancer of split-1 (HES1) 49 in nuclei of iCCA, indicating that the Notch pathway was stimulated too ( Figure 3A ).
Phospho-small mothers against decapentaplegic 2 (SMAD2), a marker of Transforming Growth Factor b (TGFb) activity, is detected at high levels only in IPNB, not in other conditions. Finally, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2/human epidermal growth factor receptor 2 (ERBB2/HER2) 50 was detected in all conditions. Microdissection of IPNBs and iCCAs from tissues of mice expressing mutant Kras G12D and treated for 25 weeks with DDC, followed by western blotting indicated that the amount of ERBB2 protein was higher in iCCA than in IPNB, and that ERBB2 was active, as evidenced by detection of phosphorylated ERBB2 Y1248 ( Figures   3A-B) . Also, RT-qPCR analysis of total RNA from normal purified cholangiocytes and from microdissected IPNB and iCCA showed higher expression of epidermal growth factor receptor (EGFR) in the lesions ( Figure 3B ).
We concluded that MAPK, AKT, Notch, TGFb and ERBB signaling were all activate during tumorigenesis in our mouse model, like in human iCCA.
IPNB and iCCA display similar gene expression profiles and overexpress Sox17 and Tns4
To gain insight into the mechanisms of tumor progression we investigated the gene expression profile of ductular proliferations, IPNBs and iCCAs in DDC-treated mice expressing mutant Kras G12D . The three types of lesions co-existed in livers treated for 25 weeks with DDC and were isolated at that stage. Microdissected iCCAs displayed the histology of early stage of invasive cancer, as illustrated in Figure 2B . Figure 2B ), the closely related gene expression pattern suggests that iCCA originate from IPNB. Nineteen genes were found to be differentially expressed between IPNB and iCCA (fold-change >2, adjusted p-value <0.05), out of which 10 were overexpressed ( Figure 4B ). Except for Aspa/ACY2, these 10 genes were also overexpressed in human iCCA versus non-tumor tissue (The Cancer Genome Atlas cohort (TCGA); n=34; http://firebrowse.org) and/or Gene Expression Omnibus cohort GSE119336 (n=15) 51 ), supporting the relevance of the mouse data with human data ( Figure 4C ).
SRY-related HMG box transcription factor 17 (SOX17) and Tensin 4/C-terminal tensin-
like protein (TNS4/CTEN) attracted our attention. Indeed, SOX17 cooperates with KRAS G12D to promote pancreatic metaplasia and tumor progression, and the focal adhesion protein TNS4 is upregulated by EGF-ERK signaling to promote tumor progression in hepatocellular carcinoma. 52, 53 RNA sequencing and RT-qPCR showed overexpression of both genes in iCCA as compared to IPNB. Microdissection of IPNBs and iCCAs from tissues of mice expressing Kras G12D and treated for 25 weeks with DDC, followed by western blotting confirmed the results for SOX17 and TNS4 at the protein level ( Figure 5A ). Sox17 and Tns4 were upregulated in iCCA as compared to control in mice as well as in humans ( Figure 4C ). SOX17 and TNS4 mRNA expression levels were correlated in human iCCA ( Figure 4D, Supplementary Figure 2 ). By immunostaining SOX17 was not detected in normal cholangiocytes or in Kras G12Dexpressing cholangiocytes. In IPNBs from DDC-treated animals expressing wild-type Kras, a low number of cells expressed SOX17 at levels slightly higher than background. In contrast, in DDC-treated animals expressing Kras G12D , patches of epithelial cells in IPNB and iCCA showed high levels of nuclear SOX17 ( Figure 5B ). SOX17 was also detected in endothelial CD31-positive cells, as expected. 54 -13 -Importantly, human liver displayed a similar profile with no detectable SOX17 in normal cholangiocytes, but with obvious expression in iCCA epithelial cells ( Figure 5C ). TNS4 was detected at the cell membrane in all tested conditions and was co-expressed with SOX17 in IPNB and iCCA ( Figure 5B ).
We concluded that iCCA and IPNB had similar RNA expression profiles and that SOX17 and TNS4 expression was induced in IPNB and increased in iCCA.
SOX17 and TNS4 are induced by EGF signaling and stimulate migration and proliferation
We next explored if ERBB2 function, KRAS activation and expression of SOX17 and TNS4 were coordinated. To this end we used cholangiocarcinoma EGI-1 cells which are known to have a mutant KRAS G12D gene. Treating EGI-1 cells with EGF stimulated expression of KRAS, SOX17 and TNS4 ( Figure 6A ). Similar results were found in EGFtreated NMC cells, an immortalized normal mouse cholangiocyte line that expresses high levels of cholangiocyte markers (Supplementary Figure 3A-B ). Since KRAS is activated downstream of EGFR/ERBB2 and is known to stimulate SOX17 expression, 52 we envisaged the possibility that SOX17 activates TNS4 to constitute a EGFR/ERBB2-KRAS-SOX17-TNS4 cascade ( Figure 6B ). We generated EGI-1 clones that stably overexpress doxycycline-inducible SOX17 or TNS4, and found that SOX17 stimulated TNS4 and to some extent KRAS expression, whereas TNS4 slightly induced ERBB2 and KRAS ( Figure 6C ). Since EGI-1 cells constitutively express KRAS G12D , we transfected NMC cells with Kras G12D to verify if it stimulates Sox17 and Tns4 in cholangiocytes; this was the case, further confirming the proposed gene cascade (Supplementary Figure 3C) .
Since TNS4 is known to promote hepatocarcinoma cell migration, 53 we verified if this was the case for biliary cells. Doxycycline-mediated induction of TNS4 in EGI-1 or NMC cells indeed accelerated cell migration in a wound healing assay ( Figure 6D ).
The assay lasted for 8h, i.e. below the duration of doubling time. More important, doxycycline-mediated increase of SOX17 or TNS4 stimulated proliferation of EGI-1 cells, as shown by crystal violet staining or Hoechst fluorescence intensity assays ( Figure 6E ). -14 - We concluded that a EGFR/ERBB2-KRAS-SOX17-TNS4 gene cascade is activated during iCCA tumorigenesis and contributes to cell migration and proliferation.
Discussion
Several genetic mouse models of cholangiocarcinoma have been generated by Cre recombinase-mediated gene alterations. [35] [36] [37] These models often induce genetic modifications at prenatal stages, or simultaneously in multiple liver cell types. For these reasons, they are not optimally suited for analysis of tumor progression starting from a well-identified adult liver cell type. Here, we selected OPN-CreER for its high efficiency and cholangiocyte specificity 38,39 to induce expression of Kras G12D , a gene frequently mutated in human iCCA, including in precursor lesions. In our mouse model, Kras G12D is expressed from its endogenous locus, meaning that the level of expression is within physiological limits. This was combined with chronic cholangitis in order to mimic tumor development in a context of chronic inflammation which is a major risk factor for iCCA.
Thus, the cell type of origin is clearly identified, and iCCA in our mouse model develops from cholangiocytes as assessed by eYFP expression. Tumorigenesis is associated with activation of the ERK, AKT, NOTCH and ERBB pathways as in many human iCCAs. Also, the mouse iCCAs display a tubular pattern with mucin-producing columnar cells, which is typical for human large duct type iCCA; intense desmoplasia was also detected. Therefore, our animal model displays many histological and biochemical features of human iCCA. Moreover, the transcriptomic profile of IPNB and early stage of invasive iCCA, together with the histological identification of junctions between the two lesions strongly suggest that iCCA derive from IPNB. Interestingly, in humans, mutant KRAS is detected already in human low-grade IPNB, and tumor progression is associated with decreased TGFb signaling, 31 as in our model which shows strong nuclear staining of p-SMAD2 in IPNB, but no detectable p-SMAD2 in iCCA. Activation of the Wnt pathway resulting from mutations in the Adenomatous Polyposis Coli (APC) or b-Catenin (CTNNB1) gene has been reported in a subset of human IPNB, 55 but we did not detect nuclear accumulation of b-catenin in our mouse model. - 
-
Fickert and coworkers described the inflammation occuring in DDC-treated livers. 47 We monitored an increase in interleukin-33 (IL-33) expression in IPNB and further in iCCA ( Supplementary Figure 4) . IL-33 is a biliary mitogen which induces iCCA when combined with expression of constitutively active AKT and Yes-associated protein, and with obstructive cholestasis 56, 57 . IL-33 is therefore likely to contribute to tumor growth in our model.
During the tumorigenic process we found that SOX17 expression in the intrahepatic cholangiocyte lineage becomes detectable at low level in IPNB of DDC-treated mice expressing wild-type Kras. In iCCA, SOX17 was heterogeneously distributed, with large epithelial cell patches displaying high expression of SOX17, while other tumor cells lacked detectable SOX17. The higher level of SOX17 in microdissected iCCA as compared to IPNB likely reflects the higher number of cells expressing the gene in iCCA, and possibly the fact that SOX17-positive epithelial cells in iCCA express higher levels of SOX17 than in IPNB cells, as evidenced by more intense immunostaining in iCCA than in IPNB. SOX17 protein is not expressed in normal human or mouse intrahepatic cholangiocytes, but regulates development of the extrahepatic biliary tract and is detected in adult gallbladder epithelium. [58] [59] [60] [61] SOX17 is also strongly expressed in endothelial cells, which means that care is needed to interpret transcriptomic and epigenomic analyses of SOX17 expression from sampled tumor tissues composed of multiple cell types. Our data suggest that higher expression of SOX17 in iCCA results, at least in part, from EGFR/ERBB2-KRAS-mediated stimulation. SOX17 is regarded as a tumor suppressor in iCCA and downregulation of its expression by promoter hypermethylation negatively affects the patients' prognosis. 62, 63 However, our data showing that SOX17 promotes proliferation point toward a pro-tumorigenic role. Similar to our findings, and in line with the similarity of tumorigenic processes in liver and pancreas, SOX17 was shown earlier to be induced in precursor lesions of pancreatic ductal adenocarcinoma, and to cooperate with oncogenic KRAS G12D to enhance transformation of normal pancreas. 52 Also, SOX17 is overexpressed in high grade malignant ERBB2-transformed tumor-derived cholangiocarcinoma cells as compared to less tumorigenic BDE-1 cells. 64 The reason for the discrepancy between our data -16 - and those of Merino-Azpitarte and coworkers who showed that overexpression of SOX17 in EGI-1 cells reduces proliferation, is not clear. We note that those authors generated stable lines which overexpressed SOX17 and which displayed heterogeneous survival rates. We therefore propose that the function of SOX17 should be investigated while considering that SOX17 levels and that the heterogeneity of cellular context might determine pro-tumorigenic or tumor-suppressing properties.
Tensins are focal adhesion proteins involved in cell migration by bridging the extracellular matrix receptors and the actin skeleton. TNS4 is activated by KRAS signaling in cultured colorectal cancer cells and pancreatic adenocarcinoma cell lines in which it enhances the motility of cells. 65 In cultured hepatocellular cancer cells TNS4 is activated by EGF-ERK signaling and also enhances cell motility. 53 In our mouse model we detect TNS4 expression already in normal cholangiocytes, and monitor an increase in its expression during tumorigenesis. Moreover, TNS4 and SOX17 co- In conclusion, we have developed a novel mouse model which recapitulates formation of iCCA precursor lesions and their evolution toward malignancy, much like in humans.
The carcinogenic process is associated with activation of a EGFR/ERBB2-KRAS-SOX17-TNS4 gene cascade that contributes to cell migration and proliferation. 
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